CoChat

Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties

Open access
Terashima, Yuya, Toda, Etsuko, Itakura, Meiji, Otsuji, Mikiya, Yoshinaga, Sosuke, Okumura, Kazuhiro, Shand, Francis H. W., Komohara, Yoshihiro, Takeda, Mitsuhiro, Kokubo, Kana, Chen, Ming-Chen, Yokoi, Sana, Rokutan, Hirofumi, Kofuku, Yutaka, Ohnishi, Koji, Ohira, Miki, Iizasa, Toshihiko, Nakano, Hirofumi, Okabe, Takayoshi, Kojima, Hirotatsu, Shimizu, Akira, Kanegasaki, Shiro, Zhang, Ming-Rong, Shimada, Ichio, Nagase, Hiroki, Terasawa, Hiroaki, Matsushima, Kouji · 2020 · Nature Communications
Cited by 101

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Tumor-associated macrophages affect tumor progression and resistance to immune checkpoint therapy. Here, we identify the chemokine signal regulator FROUNT as a target to control tumor-associated macrophages. The low level FROUNT expression in patients with cancer correlates with better clinical outcomes. Frount-deficiency markedly reduces tumor progression and decreases macrophage tumor-promoting activity. FROUNT is highly expressed in macrophages, and its myeloid-specific deletion impairs tumor growth. Further, the anti-alcoholism drug disulfiram (DSF) acts as a potent inhibitor of FROUNT. DSF interferes with FROUNT-chemokine receptor interactions via direct binding to a specific site of the chemokine receptor-binding domain of FROUNT, leading to inhibition of macrophage responses. DSF monotherapy reduces tumor progression and decreases macrophage tumor-promoting activity, as seen in the case of Frount-deficiency. Moreover, co-treatment with DSF and an immune checkpoint antibody synergistically inhibits tumor growth. Thus, inhibition of FROUNT by DSF represents a promising strategy for macrophage-targeted cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-14338-5

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 101

Metadata

Authors
Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., Chen, M.-C., Yokoi, S., Rokutan, H., Kofuku, Y., Ohnishi, K., Ohira, M., Iizasa, T., Nakano, H., Okabe, T., Kojima, H., Shimizu, A., Kanegasaki, S., Zhang, M.-R., Shimada, I., Nagase, H., Terasawa, H., & Matsushima, K.
Venue
Nature Communications
Published
2020-01-30
Volume
11
Issue
1
Pages
609-609
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3003330162
Cited by
101
References
10
FWCI
3.97
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. https://app.cochat.ai/papers/10.1038/s41467-020-14338-5
The paper
Terashima, Y., Toda, E., Itakura, M., Otsuji, M., Yoshinaga, S., Okumura, K., Shand, F. H. W., Komohara, Y., Takeda, M., Kokubo, K., Chen, M.-C., Yokoi, S., Rokutan, H., Kofuku, Y., Ohnishi, K., Ohira, M., Iizasa, T., Nakano, H., Okabe, T., . . . Matsushima, K. (2020). Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nature Communications. https://doi.org/10.1038/s41467-020-14338-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.